(New/bonus content starts at 24:11. First part of episode originally aired October 5, 2021.)
This week, Radio Advisory is bringing you an encore of Ep. 91: We need to talk about maternal health in America, where host Rachel (Rae) Woods invites Advisory Board Expert Darby Sullivan and Optum Director of social responsibility Callie Chamberlain to discuss the dire state of maternal health in America.
Following the original episode, in a special bonus segment, host Rae Woods brings back Advisory Board health equity expert Darby Sullivan and invites women’s health expert Gaby Marmolejos to discuss why maternal health, and women’s health more broadly, are only getting worse. In the conversation, they discuss what is driving poor maternal outcomes and why there needs to be a massive shift in how the industry thinks about maternal health moving forward.
This episode was recorded before the FDA approved Zurzuvae (zuranolone), the first ever pill to treat post-partum depression. Postpartum depression is a condition that affects one in eight new mothers. Previously, the only treatment available was an IV infusion approved by the FDA, which required patients to be in the hospital for 2.5 days. The move underscores the industries' need to focus on behavioral health in the postpartum period and on women’s health more broadly.
- Ep. 91: We need to talk about maternal health in America
- Revisiting our Dobbs v. Jackson predictions, 1 year later
- What's driving the 'shocking disparities' in maternal health outcomes?
- Around the nation: FDA approves first pill for postpartum depression
- Addressing the Root Causes of Maternal Health Inequity
- [JAMA] Trends in Maternal Mortality and Severe Maternal Morbidity During Delivery-Related Hospitalizations in the United States, 2008 to 2021
Visit advisory.com/workforce to get research and insights that will help you understand the current challenges providers are facing and learn how technology – including platforms you may already have – can address healthcare's biggest staffing and care delivery challenges.
Advisory Board is a subsidiary of Optum. All Advisory Board research, expert perspectives, and recommendations remain independent.